{"id":56828,"date":"2026-02-11T00:20:23","date_gmt":"2026-02-10T16:20:23","guid":{"rendered":"https:\/\/flcube.com\/?p=56828"},"modified":"2026-02-11T00:20:24","modified_gmt":"2026-02-10T16:20:24","slug":"tangji-medtech-files-hong-kong-ipo-for-first-nmpa-approved-endoscopic-obesity-device","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56828","title":{"rendered":"Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device"},"content":{"rendered":"\n

Hangzhou Tangji Medical Technology Co., Ltd.<\/strong> has filed its IPO prospectus<\/strong> with the Hong Kong Stock Exchange<\/strong>, targeting a main board listing<\/strong> to capitalize on its position as China’s pioneer in endoscopic obesity treatment<\/strong>. The company’s flagship Gastric Bypass Stent System (GBS)<\/strong>, first approved by NMPA in January\u202f2024<\/strong> as a Class III innovative medical device<\/strong>, offers a minimally invasive alternative to bariatric surgery<\/strong> for weight loss and metabolic disease management.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Hangzhou Tangji Medical Technology Co., Ltd.<\/td><\/tr>
Listing Venue<\/strong><\/td>Hong Kong Stock Exchange (Main Board)<\/td><\/tr>
Filing Date<\/strong><\/td>Week of 09\u202fFeb\u202f2026<\/td><\/tr>
Founded<\/strong><\/td>2016<\/td><\/tr>
Sector<\/strong><\/td>Medical devices \u2013 obesity and metabolic disease<\/td><\/tr>
Use of Proceeds<\/strong><\/td>Expected to fund commercialization, R&D pipeline, and manufacturing scale-up<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Flagship Product: Gastric Bypass Stent System (GBS)<\/h2>\n\n\n\n
Feature<\/th>GBS Specification<\/th>Clinical Value<\/th><\/tr><\/thead>
Design Inspiration<\/strong><\/td>Roux-en-Y Gastric Bypass (RYGB) surgery<\/strong><\/td>Mimics metabolic benefits of gold-standard bariatric procedure<\/td><\/tr>
Delivery<\/strong><\/td>Endoscopic, minimally invasive<\/strong><\/td>No abdominal incisions; reduced recovery time vs. surgery<\/td><\/tr>
Regulatory Status<\/strong><\/td>Class III innovative medical device<\/strong> (NMPA, Jan\u202f2024)<\/td>First device in China approved for endoscopic obesity treatment<\/strong><\/td><\/tr>
Mechanism<\/strong><\/td>Stent-based gastric bypass simulation<\/td>Restricts food intake and alters nutrient absorption pathways<\/td><\/tr>
Target Population<\/strong><\/td>Obese patients (BMI \u226528) with metabolic comorbidities<\/td>Bridge between lifestyle intervention and invasive surgery<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Strategic Positioning<\/h2>\n\n\n\n
Factor<\/th>Market Implication<\/th><\/tr><\/thead>
China Obesity Epidemic<\/strong><\/td>>50% of adults overweight\/obese<\/strong>; 120 million with BMI \u226528; bariatric surgery penetration <1% due to invasiveness and cost<\/td><\/tr>
Endoscopic Bariatrics Gap<\/strong><\/td>No approved devices prior to GBS<\/strong>; massive unmet need between drugs (GLP-1 shortages) and surgery<\/td><\/tr>
GLP-1 Synergy\/Competition<\/strong><\/td>GBS offers procedural alternative<\/strong> to semaglutide\/tirzepatide for patients seeking durable non-pharmacological solution<\/td><\/tr>
Innovative Device Premium<\/strong><\/td>Class III designation enables NRDL negotiation priority<\/strong> and hospital procurement preference<\/strong> under China’s medical device localization policy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Pipeline & Comprehensive Cycle Management<\/h2>\n\n\n\n
Strategic Focus<\/th>Execution Plan<\/th><\/tr><\/thead>
GBS Commercialization<\/strong><\/td>Scale manufacturing; train endoscopists in tier-1\/2 hospitals; establish reimbursement pathway<\/td><\/tr>
Product Line Expansion<\/strong><\/td>Adjunctive devices for stent management, metabolic monitoring, and patient compliance<\/td><\/tr>
Digital Health Integration<\/strong><\/td>Comprehensive cycle management platform combining device data with lifestyle coaching<\/td><\/tr>
Global Expansion<\/strong><\/td>CE Mark and FDA regulatory pathway initiation post-HK listing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Competitive Landscape<\/h2>\n\n\n\n
Competitor<\/th>Product<\/th>Status<\/th>Tangji Differentiation<\/th><\/tr><\/thead>
ValenTx<\/strong><\/td>Endoscopic bypass sleeve (US\/EU)<\/td>CE Mark; not in China<\/td>GBS first-mover China advantage<\/strong>; tailored to Asian anatomy<\/td><\/tr>
EndoBarrier<\/strong><\/td>Duodenal-jejunal bypass liner<\/td>Limited commercial traction<\/td>GBS mimics RYGB more closely<\/strong>; superior metabolic outcomes<\/td><\/tr>
GI Dynamics<\/strong><\/td>EndoBarrier variant<\/td>Financial distress<\/td>Tangji stronger balance sheet<\/strong> post-IPO; NMPA regulatory credibility<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding Tangji Medtech’s Hong Kong IPO pricing and timing, GBS commercial adoption in Chinese hospitals, and endoscopic bariatric device market expansion. Actual results may differ due to HKEX listing approval delays, reimbursement negotiation outcomes with NMPA\/NRDL, and competitive entry from global device manufacturers.-Fineline Info & Tech<\/a><\/p>\n\n\n\n